Purpose: To evaluate the efficacy and safety of intravitreal dexamethasone (DEX) implant in retinitis pigmentosa patients with cystoid macular edema (CME).
Methods: In this randomized, noncontrolled, paired-eye, single crossover clinical trial, one eye of retinitis pigmentosa patients with bilateral CME with central macular thickness of >250 µm was randomized to intravitreal DEX implant while the fellow eye was observed. Both eyes were started on topical dorzolamide. At Month 6, DEX implant was eligible for both eyes when CME was >250 µm. Patients were followed up until Month 12. Primary outcome measures were the central macular thickness and best-corrected visual acuity changes from baseline at Month 2.
Results: Fourteen patients with bilateral RP-CME were included. Study eyes showed significant central macular thickness decrease (median, -147.5 µm; P = 0.001) and best-corrected visual acuity improvement (median, +6 letters; P = 0.001) at Month 2, but not at Month 6. Intravitreal DEX implant at Month 6 produced comparable efficacy to baseline treatment in 11 fellow eyes and 12 study eyes. Topical dorzolamide did not show significant therapeutic efficacy. During 12 months, elevated intraocular pressure of >21 mmHg and cataract progression were observed in 14.3% and 40.0% of study eyes.
Conclusion: Intravitreal DEX implant can both reduce macular thickness and improve vision in RP-CME, while repeated injection is required.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IAE.0000000000002589 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of supraciliary dexamethasone implantation for macular oedema: a preliminary comparative study.
Eye (Lond)
January 2025
Department of Ophthalmology, Bursa Uludag University School of Medicine, Bursa, Turkey.
Purpose: To evaluate the efficacy and safety of dexamethasone implantation in the supraciliary (SC) space, a novel and potential effective implantation site, compared to intravitreal (IV) application.
Methods: This prospective study included 39 eyes of 38 patients with macular oedema (ME) who underwent SC and IV dexamethasone implantation (SC-DEX and IV-DEX). Patients were randomly assigned to treatment groups and followed for 3 months.
Long term efficacy and safety profile of dexamethasone intravitreal implant in retinal vein occlusions: a systematic review.
Front Med (Lausanne)
November 2024
Department of Biomedicine, Neuroscience and Advanced Diagnostic, Eye Clinic, University of Palermo, Palermo, Italy.
Background/objective: Retinal vein occlusion (RVO) is a common, sight-threatening vascular disorder affecting individuals of all ages, with incidence increasing with age. Due to its complex, multifactorial nature, treating RVO remains a clinical challenge. Currently, treatment strategies include laser photocoagulation (especially for branch RVO), anti-VEGF therapies, and intravitreal corticosteroids.
View Article and Find Full Text PDFDexmedetomidine regulates the anti-oxidation and autophagy of adipose-derived stromal cells under HO-induced oxidative stress through Nrf2/p62 pathway and improves the retention rate of autologous fat transplantation.
Front Pharmacol
November 2024
Department of Plastic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
To investigate the protective mechanism of dexmedetomidine (DEX) on adipose-derived stromal cells (ADSCs) under oxidative stress model and its promotion effect on the retention rate of adipose granule transplantation by and experiments. The experiment was divided into control group, model group (ADSCs + HO+normal serum), DEX group (ADSCs + H0+DEX drug-containing serum), autophagy agonist group (ADSCs + HO+rapamycin (RAP)+normal serum), RAP + DEX group (ADSCs + HO+normal serum), RAP + DEX drug-containing serum), autophagy inhibitor group (ADSCs + HO+chloroquine (CQ)+normal serum), CQ + DEX group (ADSCs + HO+CQ + DEX drug-containing serum). HO-1, GSH-PX, SOD and CAT in ADSCs under oxidative stress model were measured.
View Article and Find Full Text PDFSelf-Extracting Dextran-Based Hydrogel Microneedle Arrays with an Interpenetrating Bioelectroenzymatic Sensor for Transdermal Monitoring with Matrix Protection.
Adv Healthc Mater
November 2024
Department of Molecular Chemistry, Univ. Grenoble Alpes-CNRS, 38041 Grenoble, France.
Continuous glucose monitors have revolutionized diabetes management, yet such devices are limited by their cost, invasiveness, and stability. Microneedle (MN) arrays could offer improved comfort compared to invasive implanted or mm-sized needle devices, but such arrays are hampered by complex fabrication processes, limited mechanical and sensor stability, and/or cytotoxicity concerns. This work demonstrates the first crosslinked hydrogel microneedle-bioelectroenzymatic sensor arrays capable of biomarker extraction and robust transdermal continuous monitoring in artificial interstitial fluid for 10 days.
View Article and Find Full Text PDFImpact of Aflibercept vs Dexamethasone Treatment on Epiretinal Membrane Formation in Eyes with Diabetic Macular Edema.
Ophthalmol Ther
December 2024
Department of Ophthalmology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Taipei, 11217, Taiwan.
Introduction: This study aimed to investigate the impact of aflibercept and dexamethasone (DEX) on the formation of epiretinal membrane (ERM) and their treatment outcomes in eyes with diabetic macular edema (DME).
Methods: In this retrospective cohort study, medical records of 124 eyes from 429 patients diagnosed with DME were reviewed between June 2017 and June 2019. Patients were categorized into two groups: the aflibercept group (67 eyes) and the DEX group (57 eyes).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!